Recent Business Highlights
Second Quarter 2014 Highlights
Total prescriptions for Zohydro ER were 10,299 for the second quarter; 4,076 for the first four weeks of July, up 74% compared to the first four weeks of April; and 1,088 for the most recent week ended July 25 1
Total net revenue of $9.2 million
Zohydro ER net revenue of $2.4 million on prescription demand
Zohydro ER gross factory sales to wholesalers of $4.8 million during the second quarter; $11.6 million year-to-date
SAN DIEGO, Aug.
Paycom Software, Inc. (“Paycom”) (NYSE:PAYC), a leading provider of a
comprehensive cloud-based human capital management software solution,
today announced its financial results for the quarter ended June 30,
Colony Financial, Inc. (NYSE: CLNY) (the “Company”) today announced
financial results for the second quarter ended June 30, 2014 and
declares a dividend of $0.36 per share of common stock for the third
quarter of 2014.
GAMCO Investors, Inc. (NYSE:GBL) announced today that its Board of
Directors approved a quarterly dividend of $0.06 per share to all of its
Class A and Class B shareholders, payable on September 30, 2014 to its
Class A and Class B shareholders of record on September 16, 2014.
NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science
tools for translational research and developer of molecular diagnostic
products, today announced that it has received market approval from the
Australian Therapeutic Goods Administration (TGA), clearing the company
to market its Prosigna ™ Breast Cancer Prognostic Gene
Signature Assay for assessing a woman’s risk of distant recurrence of
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.